Navid Kazemi, MD
Cardiovascular Disease · Las Vegas, NVNPI 1346243367
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.0%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Medtronic at 37.4% of the total.
Across 229 payments — averaging $86.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Abbott$3K
- Eli Lilly$2K
- Penumbra, Inc.$1K
- Merck$1K
- Shockwave Medical, Inc$692
- plus $4K from 21 others
Across 100 payments — averaging $1358.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$67K
- Amgen$35K
- AstraZeneca$14K
- Boehringer Ingelheim International GmbH$11K
- Novartis$4K
- Boehringer Ingelheim Pharma GmbH & Co.kg$4K
- plus $450 from 1 others
What the payments were for
- Consulting fees$1,1696%
- Travel & lodging$7,93940%
- Food & beverage$10,54353%
- Education$1511%
- Gifts$840%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(3 entities) | 71 | $7,443 |
| Abbott | 19 | $2,900 |
| Eli Lilly | 20 | $1,909 |
| Penumbra, Inc. | 3 | $1,438 |
| Merck | 11 | $1,110 |
| Shockwave Medical, Inc | 7 | $692 |
| Boston Scientific | 5 | $647 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $625 |
| Angiodynamics, Inc. | 4 | $445 |
| Amgen | 10 | $403 |
| Abiomed | 4 | $369 |
| Impulse Dynamics (USA) Inc. | 3 | $364 |
| E.r. Squibb & Sons, L.L.C. | 5 | $252 |
| Cvrx, Inc. | 1 | $195 |
| Cardiva Medical, Inc. | 16 | $179 |
| Edwards Lifesciences | 1 | $166 |
| Pfizer | 2 | $139 |
| Amarin Pharma, Inc. | 22 | $130 |
| Novo Nordisk | 2 | $118 |
| Terumo Medical Corporation | 1 | $113 |
| Chiesi USA, Inc. | 1 | $84 |
| Bard Peripheral Vascular, Inc. | 3 | $68 |
| Alnylam Pharmaceuticals Inc. | 1 | $33 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Novartis | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Resolute$2,067
- XIENCE SKYPOINT$1,703
- ONYX FRONTIER$1,547
- Indigo$1,265
- MK-1242$703
- OPTIMIZER$692
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$534
- Auryon Laser System 100-120 Vac$407
- CoreValve Evolut$324
- DRAGONFLY OPSTAR$290
- HawkOne$274
- Impella$272
- Repatha$272
- MitraClip$229
- VERQUVO$203
- OPTIS$200
- Barostim Neo System$195
- Indigo System$173
- Edwards SAPIEN 3 Transcatheter Heart Valve$166
- SYMPLICITY G3$150
How this compares
$19,885 in reported general payments places this provider in the 85th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 397 | $450,814 |
| XareltoRivaroxaban | 114 | $130,883 |
| EntrestoSacubitril/Valsartan | 91 | $106,117 |
| Repatha SureclickEvolocumab | 48 | $49,916 |
| Repatha SyringeEvolocumab | 20 | $24,622 |
| Praluent PenAlirocumab | 20 | $23,339 |
| JardianceEmpagliflozin | 33 | $21,493 |
| VascepaIcosapent Ethyl | 22 | $9,811 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 26 | $9,730 |
| FarxigaDapagliflozin Propanediol | 15 | $8,505 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 20 | $7,457 |
| Rosuvastatin Calcium | 391 | $5,742 |
| Atorvastatin Calcium | 417 | $4,419 |
| Metoprolol Succinate | 418 | $4,335 |
| Ezetimibe | 168 | $4,278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $139 | $450,814397 claims |
| NovartisEntresto | $20 | $106,11791 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Las Vegas
- Arjun GururajLas Vegas$399K
- Branavan UmakanthanLas Vegas$109K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Chowdhury AhsanLas Vegas$41K
- Sanjay MalhotraLas Vegas$41K
- William ReshLas Vegas$39K
- Ali NamaziLas Vegas$38K
- Herbert Cordero YordanLas Vegas$38K
- Alfred DanielianLas Vegas$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.